Safety and Feasibility of Mesenchymal Stem Cell Therapy in Patients with Critical COVID-19 Infection – A Comparative Study
DOI:
https://doi.org/10.51253/pafmj.v74i4.9977Keywords:
COVID-19, ICU, Mesenchymal Stem Cell Transplantation, Mortality, Severity Score.Abstract
Objective: To determine the outcome of Mesenchymal Stem Cell therapy compared to controls in critically ill COVID-19 patients.
Study Design: Quasi-Experimental Study.
Place and Duration of Study: Department of Pulmonology, Pakistan Emirates Military Hospital, Rawalpindi Pakistan, from Oct 2020 to Apr 2021.
Methodology: We selected 104 critically affected COVID-19 cases from the COVID High Dependency Unit and Intensive Care Unit. All patients were in critical condition and were not improving on the set protocols with high oxygen dependency. In the Intervention Group (Group-A, n=52) mesenchymal stem cell transplant Group, procedure was done using an intravenous drip in addition to the standard treatment as per hospital protocol while in the Control Group (Group-B, n=52) standard treatment was given using the hospital protocol. The study outcomes were improvement in High Resolution Computed Tomography score and reduction in Fraction of Inspired oxygen (FiO2) dependency up to 28 days post-transfusion or up to discharge.
Results: The HRCT severity score (range from 0 to 40) significantly improved in MSCT Group 25.8/40±14.7/40 compared to the controls. Similarly, the FiO2 improved 0.58±0.30 in the MSCT-Group as compared to the Control-Group. Moreover, MSCT significantly decreased mortality 29(55.7%) vs 47(90.3%) compared to the controls.
Conclusion: Mesenchymal stem cell therapy is very effective in decreasing the severity of HRCT score, improving oxygenation index and mortality in critical COVID-19 patients.
Downloads
References
World Health Organization. WHO Coronovirus
Dashboard.Internet. Available at:
https://covid19.who.int/ (Accessed on June 15, 2021)
COVID-19 Statistics. Internet. Available at:
https://www.worldometers.info/coronavirus/ (Accessed on June 15, 2021)
Kyriakidis NC, López-Cortés A, González EV. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 2021; 6: 28.
https://doi.org/10.1038/s41541-021-00292-w
Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID‐19 pneumonia: A pilot study. Cell Prolif 2020; 53(12): e12947.
https://doi.org/10.1111/cpr.12947
Karlsen APF, Wiberg S, Laigaard J, Pedersen C, Rokamp KZ, Mathiesen O. A. Systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment. PLoS One 2020; 15: e0237903.
https://doi.org/10.1371/journal.pone.0237903
Yagi H, Soto-Gutierrez A, Parekkadan B. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010; 19(6): 667–679.
https://doi.org/10.3727/096368910X508762
Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol 2012; 12: 383–396. https://doi.org/10.1038/nri3209
Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012; 136(2): 133-138.
https://doi.org/10.1111/j.1365-2567.2012.03567.x
Zhao Q, Ren H, Han Z. Mesenchymal stem cells:
Immunomodulatory capability and clinical potential in immune diseases. J Cell Immunotherap 2016; 2: 3-20.
https://doi.org/10.1016/j.jocit.2014.12.001
Leng Z, Zhu R, Hou W. Transplantation of ACE2(-)
mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216-228.
https://doi.org/10.14336/AD.2020.0228
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev2020; 29(12): 747-754. https://doi.org/10.1089/scd.2020.0080
Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China. A
retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Grasselli G, Zangrillo A, Zanella A. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to
ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574-1581. https://doi.org/10.1001/jama.2020.5394
Zangrillo A, Beretta L, Scandroglio AM. Characteristics,
treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc 2020; 22(3): 200-211.
https://doi.org/10.1016/S1441-2772(23)00387-3
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223); 507-513.
https://doi.org/10.1016/S0140-6736(20)30211-7
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-1069.
https://doi.org/0.1001/jama.2020.1585
Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci 2020; 256: 117900.
https://doi.org/10.1016/j.lfs.2020.117900
Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: A review. J Infect Public Health 2020; 13(11): 1619-1629.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Sohaib Ahmed, Muhammad Zille Humayun Mirza, Maryam Hussain, Naveed Anjum, Aysha Rani, Samar Saleem
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
